anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The cranial cup is a non-invasive, non-restrictive, adjustable orthotic device that grows with the infant and maintains proper body alignment while promoting normal head shape development. While the cranial cup is not yet FDA approved, it is considered a non-significant medical device and it has successfully corrected asymmetric positional head shape deformities in hundreds of healthy newborns less than 4 months of age cared for by the Children's Hospital Boston outpatient plagiocephaly clinic. Additionally preliminary analysis of a prospective randomized controlled trial currently underway suggests that the cranial cup may be useful in prevention of positional head shape deformity in a cohort of hospitalized infants of varying gestational ages. However, the cranial cup has never been used for correction of the most common form of positional head shape deformity in hospitalized premature infants; namely dolichocephaly. Thus, the purpose of this descriptive study is to provide information on the feasibility of using the cranial cup in a small sample of prematurely born infants with dolichocephaly during the convalescent phase of their hospitalizations. Information obtained from this descriptive study will be used to determine if a larger investigation using the cranial cup is warranted in this specific patient population.
* Capillary leak syndrome (CLS), including life threatening or fatal reactions, has occurred in patients treated with Proleukin. Do not administer Proleukin to patients with significant cardiac, pulmonary, renal, and hepatic impairment. Administer Proleukin in a hospital setting with an intensive care facility. Withhold or discontinue Proleukin as recommended [see Dosage and Administration (2.4), Contraindications (4), Warnings and Precautions (5.1)].
  * Neurologic toxicities, which may be life-threatening or result in coma or permanent neurological deficits, have occurred in patients treated with Proleukin. Withhold or discontinue Proleukin as recommended [see Dosage and Administration (2.4), Warnings and Precautions (5.2)].
  * Serious Infections including sepsis and bacterial endocarditis have occurred in patients treated with Proleukin. Treat pre-existing bacterial infections prior to initiation of Proleukin therapy and withhold Proleukin as recommended [see Dosage and Administration (2.4), Warnings and Precautions (5.3)].
Potential patients for this study will be recruited by up to 10 centres specialised in prostate cancer. Study sites will be interdisciplinary, consisting of a uro-oncology sub-site, and a radiology sub-site with high-quality MRI, surgery and pathology. Study visits will be typically conducted at the recruiting sub-site, or as institutionally appropriate. Treatment visits for patients will be performed in the collaborating sub-site. Patients will be invited for study participation by the investigators in the context of specialised clinics. Interested patients will be provided with an information sheet and will undergo a detailed informed consent procedure prior to any study procedures. Recruitment will be continued until a sufficient number of patients have undergone Ferrotran® imaging and histopathological evaluation.

To compensate for an expected drop-out rate of 15% to 20%, recruitment will only be stopped as soon as at least 69 evaluable positive (patients positive) and at least 104 evaluable negative (patients negative) patients are available for analysis.
The effectiveness of ZELAPAR as an adjunct to levodopa/carbidopa in the treatment of Parkinson’s disease was established in a multicenter, randomized, placebo-controlled trial (n=140; 94 received ZELAPAR, 46 received placebo) of three months’ duration. Patients randomized to ZELAPAR received a daily dose of 1.25 mg for the first 6 weeks, and a daily dose of 2.5 mg for the last 6 weeks. All patients were treated with concomitant levodopa products and could additionally have been on concomitant dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. COMT (catechol-O-methyl-transferase) inhibitors were not allowed.

Patients with idiopathic Parkinson’s disease receiving levodopa were enrolled if they demonstrated an average of at least 3 hours of “OFF” time per day on weekly diaries collected during a 2-week screening period. The patients enrolled had a mean duration of Parkinson’s disease of 7 years, with a range from 0.3 years to 22 years.

At selected times during the 12-week study, patients were asked to record the amount of “OFF,” “ON,” “ON with dyskinesia,” or “sleep” time per day for two separate days during the week prior to each scheduled visit. The primary efficacy outcome was the reduction in average percentage daily “OFF” time during waking hours from baseline to the end of the trial (averaging results at Weeks 10 and 12). Both treatment groups had an average of 7 hours per day of “OFF” time at baseline. Table 2 shows the primary efficacy results. Patients treated with ZELAPAR had a 13% reduction from baseline in daily “OFF” time, compared with a 5% reduction for patients treated with placebo. ZELAPAR-treated patients had an average reduction from baseline of “OFF” time of 2.2 hours per day, compared with a reduction of 0.6 hours in placebo-treated patients. 

Table 2: Mean Percentage Change from Baseline in Daily "Off" Hours at End of Treatment 

(Average of Weeks 10 and 12) for Intent-to-Treat Population

Figure 1 shows the mean daily percent “OFF” time during treatment over the whole study period for patients treated with ZELAPAR vs. patients treated with placebo.

Figure 1: Mean Daily Percent "OFF" Time During Treatment Over the Whole Study Period for Patients Treated with ZELAPAR vs. Patients Treated with Placebo 

Dosage reduction of levodopa was allowed during this study if dopaminergic side effects, including dyskinesia and hallucinations, emerged. In those patients who had levodopa dosage reduced, the dose was reduced on average by 24% in ZELAPAR-treated patients and by 21% in placebo-treated patients. 

No difference in effectiveness based on age (patients >66 years old vs. <66 years) was detected. The treatment effect size in males was twice that in females, but, given the size of this single trial, this finding is of doubtful significance.
<P>PROBLEM TO BE SOLVED: To provide a new refined human protein and a diagnostic agent, etc., for cancers utilizing the protein.  <P>SOLUTION: The present invention provides a new nucleic acid molecule, a method for determining whether the nucleic acid exists or not and a method for determining cancers, based on the result. The present invention further provides a new refined human protein expressed by the nucleic acid molecule, a recombinant DNA expressing the protein, a transformant or a transductant transformed by the recombinant DNA, an antibody against the protein of the present invention and applications of the protein and nucleic acid molecule of the present invention. The nucleic acid molecule can be used as a probe for diagnosing genes and a gene source for treating genes. Discrimination of cancers can be carried out by determining whether the nucleic molecule exists in an object to be examined or not.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Do you the invention discloses recombined human chorionic gonadotrophin fusion (Human? chorionic? gonadotrophin-Fc? fusion? protein, be called for short HCG-Fc) and preparation method thereof, this HCG-Fc albumen is dimerization fusion, does its amino acid sequence hold C end to comprise successively HCG β subunit, HCG α subunit, flexible peptide linker and human IgG from N? Fc variant, compared with existing chorionic gonadotrophin, its Half-life in vivo is longer, bioavilability is higher, side effect is less. The invention still further relates to restructuring HCG-Fc fusion protein compositions and treat and/or prevent the purposes in the medicine of infertility in preparation.
Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
This intervention consists of two audio-based sessions delivered one week apart. The first session lasts approximately 30 minutes, and the second session lasts approximately 15 minutes. The sessions are audio recordings. The first session introduces information about emotion and provides instruction for how to track emotion using self-monitoring. The second session provides more information about emotion and recaps instructions for self-monitoring. Each day in the week following each session, participants receive an email with a survey asking them to report on their mood in the previous day.
There is increasing acceptance that pain in fibromyalgia is a result of dysfunctional sensory processing in the spinal cord and brain. Electrical cortical stimulation is a device-based form of therapy that is increasingly being considered as an adjuvant to current medical modalities for the treatment of chronic pain conditions such as fibromyalgia. The investigators propose that stimulation of cortical areas believed to be involved in dysfunctional sensory processing may have a beneficial influence on fibromyalgia symptoms.

The aim of this randomized double blind, placebo controlled study is to evaluate the efficacy, safety, and tolerability of noninvasive cortical stimulation in the management of fibromyalgia symptoms. More specifically, an active treatment group of subjects will receive the study's cortical stimulation protocol twice a week for 11 weeks and will be evaluated within 14 days following end of treatment, for a total timeframe of 13 weeks. In comparison, a similar group of subjects will receive the same treatment protocol without the actual stimulation signal being applied. The signal utilized is a modulated form that permits very low-intensity signals to pass through outer tissues with less attenuation due to tissue impedance. The signals are of a sufficiently low strength that they are below the level of perception. Hence subjects cannot feel the signal, and are therefore blinded to treatment arm. Investigators and clinical staff are also blinded. Outcome measures include post-treatment to baseline changes in tender points, sleep characteristics as measured by visual analog scales, and outcomes instruments including the Fibromyalgia Impact Questionnaire.
FIELD: medicine, surgery. SUBSTANCE: it is suggested to apply 96%-eythanol by injecting it into hepatic parenchyma around metastasis due to fan-shaped punctures. Thickness of alcohol-saturated area is not less than 15 mm. Injection should be carried out twice at 15-d-long interval. The present innovation stops access of nutritive substances and oxygen to tumor cells and prevents availability of tumor decomposition products in blood system. EFFECT: higher efficiency of sclerotherapy. 3 dwg, 1 ex
The invention provides a method for selecting hybridomas which produce antibodies specific to domains of a cell surface antigen which is usually not accessible at the surface of intact cells. The method employs the screening of the hybridoma clones obtained for the production of antibodies specific against the cell surface antigen by use of immunoblotting analysis, namely by screening the clones against antigen immobilized on a solid substrate such as nitrocellulose. The invention also includes those hybridomas and monoclonal antibodies when produced according to the method. The method provides monoclonal antibodies to P-glycoprotein surface antigen correlated with multidrug resistance. The antibodies are used to obtain a cDNA probe which in turn was used to select a cDNA clone encoding for a portion of the p-glycoprotein including the C-terminal end. The C-terminal portion of the P-glycoprotein comprising about 239 amino acids and localized to the cytoplasmic side of the plasma membrane contains the epitopes for binding of the monoclonal antibodies.
Autism spectrum disorder (ASD) is a common and highly heritable neurodevelopmental disorder. During the last 15 years, advances in genomic technologies and the availability of increasingly large patient cohorts have greatly expanded our knowledge of the genetic architecture of ASD and its neurobiological mechanisms. Over two hundred risk regions and genes carrying rare de novo and transmitted high-impact variants have been identified. Additionally, common variants with small individual effect size are also important, and a number of loci are now being uncovered. At the same time, these new insights have highlighted ongoing challenges. In this perspective article, we summarize developments in ASD genetic research and address the enormous impact of large-scale genomic initiatives on ASD gene discovery.
A system for the selective separation of a specific cel population  from  a  heterogeneous  cell  mixture  is  disclosed herein.   Means  are  provided  for  obtaining  a  selective  cell concentrate from the heterogeneous  cell  mixture by separating the  selective  cell  concentrate  based  upon  the  physical  or biological properties of the concentrate.  This may be done by centrifugation,  if  desired.   A  container  is  provided  having particle means, the particle means being attached to a substance that  is  active for binding to a specific desired  cell.   One brings the cell concentrate into contact with the particle means within   the  container,  for  example,  by  providing  sterile connection between the site where the cell concentrate is formed and  the  container.   This  permits  incubation  of  the  cell concentrate with the particle means, to thereby selectively bind a  specific  cell  population from the cell  concentrate to the particle means,  creating a particle/cell  conjugate.   Magnetic means  are  then  provided  for  separating  the  particle/cell conjugate  from  the  remainder  of  the  cell  concentrate.   A two-magnet system may be used to form the separation.
Modified SB 101 molecules with improved pharmacokinetic characteristics are provided. The pegylated protein has longer half life time than recombinant SB101-Fc fusion protein expressed in mammalian cells. The pegylated SB101 shows more than 70 times longer in vivo plasma half time and the fusion protein shows roughly 10 times longer half life time than unmodified SB101. Pegylated protein and fusion protein have maintained their in vitro activity similar to unmodified SB101. The SB101 fusion protein -molecules inhibit angiogenesis, block endothelial cell response to VEGF and inhibit VEGF receptor 2 protein. The modified molecules with improved pharmacokinetic characters are candidates for treatment of angiogenesis related diseases such as cancer.
Preparing an extract from plant material of the species Rumex acetosa, comprises: providing a plant material of the species Rumex acetosa; providing a first extraction agent comprising water and at least a liquid at least partially soluble in water; optionally providing a second extraction agent comprising an organic solvent; extraction treatment of the plant material with the first extraction agent to produce an extract; separating the extract from the extracted plant materials; and optionally purifying and/or concentrating the extract. Independent claims are included for: (1) an extract obtained by the above method; and (2) a medicament, medical device, cosmetic product or food supplement comprising the extract. ACTIVITY : Virucide; Respiratory-Gen. The antiviral activity of the Rumex acetosaextract was tested using plaque assay, where herpes virus infested kidney cells of the monkey of the genus Cercopithecus aethiopswas taken. The result showed that the extract showed a good antiviral activity of 98% at 0.01-1 mu g/ml and a maximum antiviral activity (100%) at 10-100 mu g/ml. MECHANISM OF ACTION : None given.
The active comparison group will receive a smartphone with the WebMD® health information application preloaded and a BP monitor. After recruitment, participants will receive a confirmatory interview, informed consent, and baseline device training via telephone, delivered by an experienced research assistant. Participants will be encouraged to complete 1 morning BP reading daily, irrespective of study arm. BP readings are automatically uploaded via Bluetooth to a centralized, secure platform to be accessible to the study PI.
Placebo ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.
This is a Phase I, open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), 2-panel, sequential treatment study. In this study 24 healthy participants will be randomly assigned equally to 2 panels. In Panel 1 the participants will receive telaprevir in Part 1 (telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750 mg dose in the morning on Day 10) and phenytoin/telaprevir in Part 2 (phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750 mg dose in the morning on Day 17). In Panel 2 the participants will receive telaprevir (telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750 mg dose in the morning on Day 10) and carbamazepine/ telaprevir (carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 200-mg dose in the morning on Day 17). In both panels, Part 1 and Part 2 are separated by a washout period of at least 2 weeks and maximum 4 weeks. Safety and tolerability will be assessed by evaluating adverse events, electrocardiogram, clinical laboratory examinations, vital signs and physical examination throughout the study period.
PURPOSE:To provide the film for a first-aid plaster adhesive which is soft, has stretchability, is fast in stress relieving at the time of elongating, does not compress a lesion and has good hand feeling by using a polypropylene (PP) resin having a specific weight average mol.wt. and the elution amt. of the resin of a specific value at a specific value as the resin for the film for the first-aid plaster adhesive. CONSTITUTION:The PP resin which has 80000 to 500000 weight average mol.wt. and of which the elution amt. of the resin at 0 deg.C to 10 deg.C by a cross discrimination method is within a 45 to 80wt.% range of the amt. of the total PP resin, the elution amt. of the resin at 10 deg.C or over to 70 deg.C within a 5 to 35wt.% range of the amt. of the total PP resin, the elution amt. of the resin at 70 deg.C or over to 95 deg.C within a 1 to 30wt.% range of the amt. of the total PP resin and the elution amt. of the resin at 95 deg.C or over to 125 deg.C within a 5 to 35wt.% range of the amt. of the total PP resin. As a result, this film for the first-aid plaster adhesive is used as the film for the objective plaster which does not contain a plasticizer, is soft, has the stretchability, is fast in stress relieving at the time of elongating, does not compress the lesion and has the good hand feeling.
The pathogenesis of trauma-induced heterotopic ossification (HO) in the tendon remains unclear, posing a challenging hurdle in treatment. Recognizing inflammation as the root cause of HO, anti-inflammatory agents hold promise for its management. Malvidin (MA), possessing anti-inflammatory properties, emerges as a potential agent to impede HO progression. This study aimed to investigate the effect of MA in treating trauma-induced HO and unravel its underlying mechanisms. Herein, the effectiveness of MA in preventing HO formation was assessed through local injection in a rat model. The potential mechanism underlying MA's treatment was investigated in the tendon-resident progenitor cells of tendon-derived stem cells (TDSCs), exploring its pathway in HO formation. The findings demonstrated that MA effectively hindered the osteogenic differentiation of TDSCs by inhibiting the mTORC1 signalling pathway, consequently impeding the progression of trauma-induced HO of Achilles tendon in rats. Specifically, MA facilitated the degradation of Rheb through the K48-linked ubiquitination-proteasome pathway by modulating USP4 and intercepted the interaction between Rheb and the mTORC1 complex, thus inhibiting the mTORC1 signalling pathway. Hence, MA presents itself as a promising candidate for treating trauma-induced HO in the Achilles tendon, acting by targeting Rheb for degradation through the ubiquitin-proteasome pathway.
The CHILD Cohort Study is a prospective longitudinal birth cohort study. It is an observational study of healthy term infants in Canada (Vancouver, Edmonton, Manitoba, Toronto). The birth years were between 2009-2012, and is currently at the 8 year postnatal follow up phase. IMiC will receive 400 breast milk samples from 400 dyads (100/site) that were taken between 3-4 months postnatal.
PNF stretching techniques will be applied in addition to ESWT. PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
PURPOSE: To obtain a taxane-type diterpene compound useful for a medicine, etc., of overian cancer, breast cancer and lung cancer, etc., in a high productivity by culturing tissue or cell, etc., of a plant producing a taxane-type diterpene in a medium containing fatty acids and recovering a product from the resultant cultured material. CONSTITUTION: A tissue and/or cell of a plant (e.g. Taxus brevifolia NUTT) producing taxane-type diterpene (e.g. taxol, et.) is cultured in a medium containing 10-22C fatty acids such as oleic acid, linoleic acid, linolenic acid, arachidonic acid, capric acid, decenoic acid, lauric acid, dodecenoic acid, myristic acid, palmitic acid, stearic acid, eicosapentaenoic acid or docosahexaenoic acid in a concentration of 0.01-1000μM. The object taxane-type diterpene useful for a remedy of ovarian cancer, breast cancer and lung cancer, etc., is obtained in a high productivity by recovering the taxane-type diterpene from the resultant cultured material.